The October Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.
Do not hesitate to contact us with comments or suggestions.
News
We are now druginteractionsolutions.org
We have changed our domain to match our new name of UW Drug Interaction Solutions. We feel this name change better reflects our expanding activities and offerings.
All old bookmarks and links will still work, they will be redirected to the same page on our new domain.
If you have any questions or issues please contact us.
As always, don’t forget to check us out and follow us on Linked.
New queries available for beta testing
New queries are now available for beta testing under “FDA Marker Queries”. They allow you to search for in vitro and clinical data for inhibitors of CYP markers, and, in a second step from the query results page, view clinical concentrations of each inhibitor.
We are looking forward to your feedback!
September Newsletter available
The September Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.
Do not hesitate to contact us with comments or suggestions.
August Newsletter available
The August Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.
Do not hesitate to contact us with comments or suggestions.
ISSX Posters available in the Resource Center
The posters presented at the 12th International ISSX Meeting in Portland by the DIDB team are now available in the Resource Center’s DIDB Team’s Most Recent Communications section:
- “Main mechanisms of PK DDIs triggering label recommendations for drugs approved by FDA in 2018” (Dr. Jingjing Yu et al.)
- “Variability of OATP1B1/1B3 in vitro inhibition constants and the resulting impact on clinical evaluation” (Dr. Savannah McFeely et al.)
Update of our website to come soon
We will be updating the homepage and the public content of our website over the coming few weeks, with an early version released next week. Our new program name, UW Drug Interaction Solutions, reflects our expanding activities and offerings. You can view/download a new brochure and technical flyers on our redesigned homepage.
Note that once you have logged in, the web pages dedicated to subscribers have not changed and you will find all the queries, functions, and editorial content you are used to.
We have also launched a LinkedIn page for UW Drug Interaction Solutions where you can find the most recent news and events regarding the program.
UW Drug Interaction Database team to attend the 12th International ISSX Meeting
The UW Drug Interaction Database team will be attending the 12th International ISSX Meeting in Portland next week. In addition to our booth #316, we hope to meet you at one of our posters:
- “Main mechanisms of PK DDIs triggering label recommendations for drugs approved by FDA in 2018”; presented by Dr. Jingjing Yu on July 29 at 11am
- “Variability of OATP1B1/1B3 in vitro inhibition constants and the resulting impact on clinical evaluation”; presented by Dr. Savannah McFeely on July 31st at 12:30pm.
Lists of Sensitive Substrates, Inhibitors and Inducers updated
The lists of sensitive substrates, inhibitors, and inducers have been updated and are available in the Resource Center. For your convenience, we have also added the individual Excel files.
As always, feel free to contact us if you have any questions or comments.
July Newsletter available
The July Newsletter is now available. You can see this and past newsletters in the DIDB Resource Center. Please note that you must be signed in to access.
Do not hesitate to contact us with comments or suggestions.